YD Bio (YDES) News
NASDAQ: YDESHealth CareMedical SpecialitiesUSD
4.83+0.27 (+5.92%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
YDES news summary
We found 3 recent headlines mentioning YD Bio (YDES): 0 in the past week and 2 in the past 30 days, most often from GlobeNewswire, Nasdaq. YDES is making an outsized move today, up 5.92% at $4.83, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "YD Bio Expects FDA Feedback On Dry Eye Candidate By January 4, 2027", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest YD Bio headlines
- YD Bio Expects FDA Feedback On Dry Eye Candidate By January 4, 2027(RTTNews) - Biopharmaceutical company, YD Bio Ltd. (YDES) said the U.S. Food and Drug Administration granted its INTERACT meeting request for YDB-LMSCEV-001, an investigational biologic eye drop for…NasdaqYDES, ET
- YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye DiseaseFDA agrees to provide written guidance by January 4, 2027, to support development of YDB-LMSCEV-001GlobeNewswire
- YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness ProgramsTAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer…GlobeNewswire